U.S. Serial No.: 10/714,067

Title: "Novel Antiangiogenic Peptide Agents and Their Therapeutic and Diagnostic Use"

Filed: November 14, 2003

Response to Office Action of February 7, 2007

Page 2 of 7

## Amendments to the Claims

The currently pending claims are below. Please amend the claims following, wherein the deleted matter is shown by strikethrough and the added matter is shown by underlining. This listing of claims replaces all prior versions, and listings of claims in the application.

- 1. (Canceled)
- 2. (Canceled)
- 3. (Canceled)
- 4. (Currently amended) An The isolated peptide of claim 1 having the amino acid sequence of SEQ ID NO: 24.
- 5. (Canceled)
- 6. (Canceled)
- 7. (Canceled)
- 8. (Canceled)
- 9. (Canceled)
- 10. (Canceled)
- 11. (Canceled)
- 12. (Canceled)
- 13. (Canceled)
- 14. (Canceled)

AO 1621111.1 2

U.S. Serial No.: 10/714,067

Title: "Novel Antiangiogenic Peptide Agents and Their Therapeutic and Diagnostic Use"

Filed: November 14, 2003

Response to Office Action of February 7, 2007

Page 3 of 7

- 15. (Canceled)
- 16. (Canceled)
- 17. (Canceled)
- 18. (Canceled)
- 19. (Canceled)
- 20. (Canceled)
- 21. (Canceled)
- 22. (Withdrawn, Currently amended) A method of treating an angiogenic disease in a subject, the method comprising administering to a subject in need of such treatment an angiogenesis inhibitory effective amount of an The method of claim 21, wherein the isolated peptide that has the amino acid sequence of SEQ ID NO:24.
- 23. (Canceled)
- 24. (Withdrawn, Currently amended) A method of inhibiting tumor formation or growth in a patient, the method comprising administering to the patient an angiogenesis inhibitory effective amount of an The method of claim 23, wherein the isolated peptide that has the amino acid sequence of SEQ ID NO:24.
- 25. (Canceled)
- 26. (Withdrawn, Currently amended) A method of modulating vascularization of a patient's placenta, the method comprising administering to the patient an angiogenesis inhibitory effective amount of the isolated peptide of <u>claim 4 elaim 1</u>.

3

AO 1621111.1

U.S. Serial No.: 10/714,067

Title: "Novel Antiangiogenic Peptide Agents and Their Therapeutic and Diagnostic Use"

Filed: November 14, 2003

Response to Office Action of February 7, 2007

Page 4 of 7

- 27. (Currently amended) A pharmaceutical formulation, comprising:
  - a pharmaceutically acceptable carrier; and
  - a therapeutically effective amount of an isolated a peptide that has the amino acid sequence of as shown in SEQ ID NO:24.
- 28. (Withdrawn, Previously presented) A method of treating, comprising:
  diagnosing a patient as having a tumor; and
  administering to the patient an angiogenesis inhibitory effective amount of the
  formulation of claim 27.
- 29. (Currently amended) The isolated anti-angiogenic peptide of Claim 4 Claim 1, wherein the anti-angiogenic peptide inhibits capillary endothelial cell proliferation and organization; inhibits angiogenesis in chick chorioallantoic membrane; and binds to at least one specific receptor which does not bind an intact full length growth hormone.
- 30. (Canceled)
- 31. (Canceled)
- 32. (Canceled)

AO 1621111.1 4